Boldenone undecylenate is a very versatile drug, and can be combined with a number of other agents depending on the desired result. For mass, it is commonly stacked with an injectable testosterone such as enanthate or cypionate. This should produce strong gains in muscle size and strength, without the same intensity of side effects of using testosterone (at a higher dose) alone. During a cutting phase, muscle hardness and density can be greatly improved when combining boldenone undecylenate with a non-aromatizable steroid such as trenbolone acetate or methenolone enanthate. Oral c-17 alpha alkylated agents such as fluoxymesterone or stanozolol may also be used, but will present some level of hepatotoxicity. For some, even the low buildup of estrogen associated with this compound is enough to relegate its use to bulking cycles only.
However, in December 2004 the United States the 14-member Food and Drug Administration (FDA) advisory committee, plus voting consultants, for Reproductive Health Drugs unanimously rejected Procter and Gamble's fast-track request for Intrinsa citing concerns about off-label use . In Canada, post-menopausal women have been able to obtain government-approved testosterone treatment since 2002. In Australia, post-menopausal women can use Organon testosterone implants which have to be surgically inserted and last from three to six months.